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made in the dissection of the molecular events leading to perito-Toward better dialysis compatibility: Advances in the biochem-
neal membrane failure open new avenues to develop safe, moreistry and pathophysiology of the peritoneal membranes. Perito-
biocompatible peritoneal dialysis technologies.neal dialysis (PD) has modified our concept of the peritoneal
membrane, which is now a topic of active research. Peritoneal
solute transport progressively increases with time on PD, en-
hances the dissipation of the osmotic gradient and, eventually, Peritoneal dialysis (PD) is now an established alterna-
reduces ultrafiltration capacity. The causes of peritoneal mem-
tive in the treatment of end-stage renal failure. It is uti-brane failure remain elusive. Recurrent episodes of peritonitis
lized in approximately 15% of the dialysis patients in theare not a prerequisite for the development of ultrafiltration
developed world [1]. It has proven to be better than hemo-failure. Functionally, the changes of the failing peritoneal mem-
brane are best described as an increased functional area of dialysis, especially in its protection of residual renal func-
exchange for small solutes between blood and dialysate. Histo- tion [2] and in the lower overall cost to society [3]. Its
logically, these events are associated with vascular proliferation use has been limited by the morbidity associated with
and structural changes of pre-existing vessels. Gathered evi- acute peritonitis episodes, a problem recently overcomedence, including information on the composition of peritoneal
by newer technical devices and better antibiotic manage-cavity fluids and its dependence on the uremic environment,
ment. The major remaining problem is the progressivehave cast a new light on the molecular mechanisms of decline
in peritoneal membrane function. Chronic uremia per se mod- deterioration of the peritoneal membrane structure and
ifies the peritoneal membrane and increases the functional area function [4], which curtails its use in approximately 50%
of exchange for small solutes. Biochemical alterations in the of PD patients within five years [5]. Cross-sectional and
peritoneum inherent to uremia might be, at least in part, ac- longitudinal studies have shown that peritoneal solutecounted for by severe reactive carbonyl compounds overload
transport progressively increases with time on PD, en-originating both from uremic circulation and PD fluid (“perito-
hances the dissipation of the osmotic gradient, and even-neal carbonyl stress”). The molecular events associated with
long-term PD are similar but more severe than those present tually reduces ultrafiltration capacity [6–8]. This in-
in chronic uremia without PD, including modifications of nitric creased small solute transport rate mainly reflects the
oxide synthase (NOS) and angiogenic growth factors expres- peritoneal vascular surface area [4]. A raised peritoneal
sion, and advanced glycation and lipoxidation of the peritoneal membrane permeability is associated not only with tech-proteins. This review focuses on reactive carbonyls and their
nique failure, but also with increased mortality and mor-association with a number of molecular changes observed in
bidity in PD patients [9].peritoneal tissues. This hypothetical approach will require fur-
The causes of peritoneal membrane failure remain elu-ther testing. Nevertheless, the insights gained on the peritoneal
membrane offer a new paradigm to assess the effect of uremic sive. Although recurrent episodes of peritonitis with as-
toxins on serosal membranes. Furthermore, the progresses sociate inflammatory changes damage the peritoneal
membrane over time [10], they are by no means a prereq-
uisite for the development of ultrafiltration failure [4, 11].
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mechanisms of decline in peritoneal membrane functionstress, advanced glycation end products, glucose degradation products.
during PD therapy. This review summarizes a few of
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pothesis on the molecular events leading to alterations of DOES UREMIA MODIFY THE PERITONEAL
MEMBRANE REGARDLESS OF PD?the peritoneal membrane transport and, finally, discusses
therapeutic perspectives toward more effective and bio- Until very recently it was generally accepted that the
medically more suitable PD technologies. peritoneal membrane was unaffected by uremia, al-
though an increased permeability had been already doc-
umented [26]. In a rat model of chronic uremia, Combet
THE PERITONEAL MEMBRANE: A UNIQUE et al observed structural modifications including subme-
AND EFFICIENT EXCHANGE SURFACE sothelial and perivascular fibrosis, and angiogenesis [27].
BETWEEN BLOOD AND DIALYSATE These changes were matched by functional modifications
characterized by an augmented permeability for small so-The histology of the peritoneal membrane has been
lutes. Several potential mediators identified thus far in-clearly described to include the mesothelium, interstitial
clude VEGF and FGF2 expression, followed by endothe-space, and blood microvessels. Under normal physiologi-
lial NOS (eNOS) and neuronal NOS (nNOS), as they werecal conditions, the mesothelial layer [4, 12, 13] and inter-
transiently up-regulated after subtotal nephrectomy. The
stitial tissue [14, 15] are not thought to be important severity of these various uremia-induced alterations cor-
barriers at least for small solute transport. By contrast, related with the degree of renal failure. Of note, a simi-
the peritoneal vascular walls, mainly through their endo- lar increase in FGF2 expression has been observed in
thelium, are the main obstacles to small solute transport the peritoneum of uremic patients, prior to the initia-
during PD [12, 13]. tion of dialysis (Ferrier ML and Devuyst O, unpublished
In standard PD using glucose as the osmotic agent, observation).
the peritoneal membrane exchange potential has been In addition to changes in some factors already present
evaluated by clinical tools such as the peritoneal equilib- in the normal rat peritoneum, uremia is associated with
rium test (PET) and sodium sieving. Its efficiency relies vascular deposits of Nε-carboxymethyllysine (CML) and
pentosidine [27], two well-known epitopes generated byon the osmotic gradient between peritoneal fluid and
advanced glycation, that is, advanced glycation end prod-plasma as it allows water influx, the diffusion of small
ucts (AGEs). Their localization coincides with that ofuremic solutes evaluated by urea and creatinine, and the
overexpressed VEGF and FGF2. In contrast to the ratcounter diffusion of glucose.
model, in humans AGE modification of peritoneal pro-The results of the PET and sodium sieving have been
teins appears, at best, faint [28, 29].modeled and a series of pores have been described [16]:
The peritoneal membrane structural alterations de-ultrasmall pores (0.3 nm) for water, small pores (4 to
tected in the uremic rat model have been supported in5 nm) for water and smaller solutes such as urea and
humans [30, 31]. Even in non-dialyzed uremic patients,
glucose, and large pores (15 nm) for all the former
submesothelial fibrosis is present and the density of ves-
constituents and large solutes. The fact that 50% of the sels increased, as compared to non-uremic controls. Al-
ultrafiltration during 2.27 or 3.86% dwell occurs through together, these data suggest that biochemical alterations
the ultrasmall pores illustrates their major clinical impor- inherent to uremia per se modify the peritoneum prior
tance in PD patients [17]. to the use of PD, and thus provide a paradigm to better
Recent studies have identified a number of molecules understand the modification of the several serosal mem-
that functionally mediate the peritoneal membrane char- branes in uremia.
acteristics. The water channel aquaporin-1 (AQP-1) is
located in the apical and basolateral membranes of endo-
CHANGES IN THE PERITONEAL MEMBRANE
thelial cells lining non-fenestrated capillaries in numer- DURING PD
ous tissues including the peritoneum [18]. Several lines
The permeability characteristics of the peritoneal mem-of evidence demonstrate that AQP-1 is the molecular
brane are progressively modified during PD, imposing oc-counterpart of the ultrasmall pore of the peritoneal mem-
casional switching of the patient from PD to hemodialysis.
brane [19, 20]. The small and large pores are not yet
specifically identified. Additional molecules include ni- Functional analysis
tric oxide (NO)/nitric oxide synthase (NOS) [21, 22], The most striking functional characteristics of perito-
vascular endothelial growth factor (VEGF) [23], and neal membrane failure are detected in patients on
basic fibroblast growth factor (FGF2) [24]. Both VEGF chronic PD by the PET test and a measure of sodium
and FGF2 are instrumental in vascular proliferation and sieving [4, 6–8]. These characteristics include a loss of
neo-angiogenesis. In addition, FGF2 mediates fibrotic free water permeability identified by the disappearance
changes of the interstitium and smooth muscle cell prolif- of sodium sieving, an increased transport rate of small
solutes (urea, creatinine and glucose), with an attendanteration [25].
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enhanced dissipation of the glucose-dependent osmotic and that these covalent modifications modulate the func-
tion of several proteins [43]. Interestingly, preliminarygradient across the peritoneal membrane and the loss of
ultrafiltration capacity. data suggest that S-nitrosylation of a single cysteine
within the functional pore of AQP-1 is associated withThe changes in the functional characteristics of the
failing peritoneal membrane are best described as an a significant loss of water permeability [43, 44]. This
finding might help understand the mechanisms of theincreased functional area of exchange for small solutes
between blood and dialysate, the so-called “effective decreased water permeability of the peritoneal mem-
brane despite a normal expression of AQP1 [35, 45].peritoneal surface area” (EPSA) [4, 12]. They rely on
enhanced angiogenesis (described below) and, possibly, It is interesting that in an acute peritonitis rat model,
ultrafiltration failure is associated with a major, tenfoldvasodilation of peritoneal vessels. The increased trans-
port of small solutes stands in contrast with the impaired increase in peritoneal NOS activity due to the up-regula-
tion of both eNOS and inducible NOS (iNOS) [45]. Inwater transport, witnessed by the fading sodium sieving.
this model, up-regulated eNOS is paralleled by a signifi-
Histological analysis cant increase in vascular density, whereas inflammatory
derived cytokines activate the transcription of iNOS.Histopathologic studies have revealed that prolonged
PD is associated with profound modifications of the peri- In humans on long-term PD, regulation of NOS also
might be involved in the increased EPSA [33]. Peritonealtoneal membrane. First, an increased density of blood
vessels, documented in a rat model of long-term PD NOS activity increases fivefold above control levels and
is positively correlated with the duration of PD. In-[32], has been recently confirmed in humans [31, 33,
34]. Quantification of factor VIII immunoreactivity in creased NOS activity is solely mediated by calcium-
dependent eNOS. Its biological relevance is further dem-peritoneal sections from long-term PD patients, showed
a 2.5-fold increase in the density of stained vessels in onstrated by concomitant, enhanced immunoreactivity
for nitrotyrosine, which points to oxidative stress andlong-term PD patients as compared to non-uremic con-
trols [33]. The endothelial area also was increased in the increased peroxynitrite formation.
PD patients [33]. Thus, PD progressively increases the Several factors might contribute to the increased
EPSA as the result of vascular proliferation and, possi- expression of eNOS in long-term PD patients. eNOS
bly, of a vasodilation of pre-existing vessels. Interstitial up-regulation reflects, at least in part, vascular prolifera-
fibrosis and mesothelial alterations have been reported tion and thus increased endothelial surface area. In addi-
in addition to the vascular changes [30, 31, 34]. tion, it may be modulated by changes in immune defense
systems induced by long-term PD, such as, local cytokine
Molecular biological analysis production [46]. Observations that eNOS is up-regulated
In humans, the molecular events associated with long- in the inflammatory peritoneum [18] or upon virus-
term PD and peritoneal membrane failure are similar induced activation of interferon- and tumor necrosis
but more severe than those present in chronic uremia factor- support the latter hypothesis [47].
without PD. They include up-regulation of eNOS, over- In long-term PD patients, advanced glycation and ad-
expression of VEGF and FGF2, and advanced glycation vanced lipoxidation of peritoneal proteins becomes a
of peritoneal proteins [33]. In contrast, the expression striking feature [28, 29]. Prior to the onset of PD, in con-
of AQP1, the pore involved in water transport, remains trast with uremic rats, the AGEs and advanced lipo-
apparently unaffected [35]. oxidation end products (ALEs) in humans are only faintly
The up-regulation of VEGF and FGF2 fits with an detectable. They increase subsequently in parallel with
enhanced angiogenesis and the interstitial fibrosis ob- PD duration. Of interest, AGEs colocalize with VEGF
served on histological analysis: its determinants are dis- along the endothelium lining peritoneal blood vessels
cussed later in this article. The increased NOS activity [33, 48], and several studies have hypothesized that AGE
is also of considerable interest as NO has been shown to modification of the peritoneum plays a critical role in its
be clinically relevant [36–38]. Under some circumstances, functional alteration [27–29, 33, 49].
the NO donor, nitroprusside, enhances both the EPSA
and the intrinsic permeability of the membrane both in
PERITONEAL CARBONYL STRESS: THEanimal models and in PD patients, whereas NOS inhibi-
CAUSE OF AGE MODIFICATION OFtors such as L-NAME have the reverse effect. These
THE PERITONEAL MEMBRANEeffects of NO are in good agreement with its previously
Advanced glycation of proteins is induced by reactivedescribed activities in other systems [39–42]: NO aug-
carbonyl compounds (RCOs) [50]. Several RCOs lead-ments vascular permeability and modulates the expres-
ing to the formation of AGE epitopes such as pentosi-sion and activity of VEGF. Furthermore, there is accu-
dine [51] or CML [52] have been identified, for example,mulating evidence indicating that under physiological
conditions, NO targets cysteine thiols by S-nitrosylation glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone
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(3-DG), glycolaldehyde, and arabinose [53–56]. While enzymatic mechanisms also might contribute to a de-
creased removal of RCOs and thus to the uremic car-many others are present and can be estimated by the
2,4-dinitrophenylhydrazine (DNPH) method, their iden- bonyl stress.
tity remains elusive [29]. In PD, RCOs precursors of
Peritoneal carbonyl stressAGEs may originate from two sources: the peritoneal
dialysate and the uremic circulation [29]. We recently demonstrated that not only PD fluid, but
also serum-derived RCOs contribute to the genesis of
RCOs originating from glucose containing PD fluid peritoneal AGEs [29]. During the peritoneal dwell time,
the RCO content of commercial heat-sterilized glucoseHeat sterilization of PD fluids degrades glucose into
products including RCOs, such as GO, MGO, and 3-DG. PD fluids, that is, GO, MGO and 3-DG, as well as glucose
levels fall markedly. In contrast, during the same timeResearch on the role of AGEs in the peritoneum has
focused mostly on these RCO precursors [57–59]. interval, total RCO levels (assessed by the DNPH
method) increase progressively in the dialysate toward
RCOs originating from uremic circulation concentrations similar to those observed in plasma. This
pattern is compatible with an outward diffusion of GO,Plasma RCO precursors of AGEs also have to be
taken into consideration as they invade the peritoneal MGO, 3-DG from the peritoneal cavity and an inward
diffusion of plasma RCOs within the peritoneal fluid.cavity during the dwell time [29]. RCOs, derived not
only from carbohydrates but also from lipids, accumulate Plasma derived RCOs are instrumental in the genesis
of AGEs, as the generation of pentosidine and CMLin uremic plasma (“carbonyl stress”) and contribute to
the production of AGEs as well as of ALEs in the body after incubation of PD effluent increases progressively
with dwell time. Further evidence for their role in the mod-[50]. Their accumulation in uremic plasma has been
demonstrated, for example, in in vitro incubation experi- ification of peritoneal membrane proteins is provided by
the demonstration that ALEs, such as malondialdehydements during which pentosidine, an AGE moiety, in-
creases over time [60]. Addition of inhibitors of the car- (MDA)-lysine and 4-hydroxynonenal (HNE)-protein
adduct, appear together with AGEs in the peritoneumbonyl amine reaction, such as aminoguanidine [61] or
2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylace- of long-term PD patients [29]. As already mentioned,
uremic plasma RCOs are derived not only from carbohy-tanilide (OPB-9195) [62, 63], represses the production
of pentosidine, pointing to the RCO nature of the pentos- drates, but also from lipids. The former produce AGEs
and the latter produce ALEs. During their diffusionidine precursors. Notably, plasma pentosidine levels are
correlated with the level of in vitro pentosidine gener- within the peritoneal cavity, uremic RCOs are thus ex-
pected to generate not only AGEs, but also ALEs. Theated after incubation [60], suggesting that they mirror
the level of RCO precursors and therefore might be used presence of the latter adducts, which cannot proceed
from glucose degradation products present in commer-as a marker of their accumulation [64].
Several mechanisms might account for RCO accumu- cial heat-sterilized glucose PD fluids, confirm the role
played by circulating RCOs crossing the peritoneal mem-lation in renal failure [65]. Production of RCOs might be
enhanced by the oxidative stress associated with uremia brane during PD.
Advanced glycation end products and ALEs are only[66]. This hypothesis is supported by the positive correla-
tions demonstrated in uremic serum between the levels faintly present in the peritoneum of uremic patients prior
to the onset of PD [28, 29]. Their marked rise after theof pentosidine and markers of oxidative stress such as
advanced oxidation protein products (AOPP) [67], de- onset of PD suggests that their formation is enhanced
by the augmented mass transfer of plasma RCOs acrosshydroascorbate [68] and superoxide dismutase [69], as
well as by the negative correlation reported between the peritoneal membrane into the peritoneal cavity,
likely as a result of the dialysis procedure itself.serum pentosidine and glutathione peroxidase levels
[69]. Alternatively, the rise in RCOs in uremia could be The major RCOs that diffuse from uremic circulation
into the peritoneal cavity have yet to be identified. Theyaccounted for by a decreased removal by the failing
kidneys [64, 70] and/or through enzymatic pathways of are not GO, MGO, or 3-DG [29].
detoxification such as the glyoxalase pathway [54]. In
Pathological significance of carbonyl stressthe latter pathway, RCOs such as MGO and GO react
reversibly with glutathione and are subsequently detoxi- The peritoneal cavity of PD patients is thus in a state
of severe overload of RCOs derived both from uremicfied by glyoxalases I and II into d-lactate and glutathione.
Decreased levels of glutathione therefore can augment circulation and from conventional glucose-based PD flu-
ids. Which role do these RCOs play in the pathogenesisthe levels of a wide range of RCOs. Glutathione concen-
tration in red blood cells and the serum activity of gluta- of peritoneal membrane deterioration?
As stated earlier, RCOs promote the AGE and ALEthione-dependent enzymes are significantly reduced in
uremic patients [69, 71, 72]. Other, as yet unexplored modification of proteins. In vitro, AGE and ALE modi-
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fied proteins initiate a range of cellular responses [73–78], strategies (Fig. 1). Although each step has been docu-
mented in vitro, the entire hypothesis remains to beincluding stimulation of monocyte chemotaxis and apo-
ptosis, secretion of inflammatory cytokines from macro- validated in vivo, that is, by testing its various therapeu-
tic implications.phages, proliferation of vascular smooth muscle cells,
stimulation of platelet aggregation, and of VEGF pro- Chronic uremia per se modifies the peritoneal mem-
brane and increases the EPSA. Biochemical alterationsduction from endothelial cells. Independently of their
AGE- and ALE-mediated effects, RCOs also interfere in the peritoneum inherent to uremia, at least in part,
might be accounted for by severe RCO overload origi-with various cellular functions and induce both structural
and functional alterations of proteins. For example, ex- nating both from uremic circulation and PD fluid (“peri-
toneal carbonyl stress”). Plasma RCOs derived fromposure in vitro of cultured mesothelial and endothelial
cells to MGO increases mRNA and protein synthesis of both carbohydrates and lipids accumulate in the uremic
circulation and slowly diffuse into the peritoneal cavity.VEGF [48]. Repeated intraperitoneal loads of MGO,
given to rats, also increase the peritoneal membrane They initiate a faintly detectable AGE as well as ALE
protein modifications. During PD, RCOs resulting fromexpression of VEGF in vivo [48]. Noteworthy in this
heat-sterilization of glucose PD fluid enter the perito-context is the demonstration that, both in long-term PD
neum, and are complemented by an increased mass trans-patients and in the chronic uremic rat model [33, 48], an
fer of serum RCOs due to the dialysis procedure itself.increasing staining for AGEs, CML and pentosidine is
The peritoneal carbonyl stress accelerates the AGEdetected in peritoneal arterial walls together with an
and ALE modification of proteins. AGEs as well as theiraugmented VEGF and FGF2 expression.
RCO precursors are known to initiate a number of cellu-There are two major pathways (direct and indirect)
lar responses. We hypothesize that they stimulate cyto-through which carbonyl stress is sensed by cells and trig-
kine and growth factors (including VEGF) productiongers a cascade of intracellular signal transduction. In the
and regulate NOS expression in peritoneal cells. The com-indirect pathway, the RCOs first interact with proteins
bination of VEGF and NO stimulates angiogenesis, in-or lipids in the physiological environment surrounding
creases permeability, and vasodilates peritoneal capillar-the cells, which then undergo nonenzymatic glycation
ies. These combined modifications increase EPSA, whichand lipoxidation resulting in the production of AGEs
results in faster than normal dissipation of the osmoticand ALEs. They bind with the receptor(s) on cell sur-
and an eventual loss of ultrafiltration. The up-regulationfaces, such as RAGE, thereby initiating intracellular sig-
of FGF2 and transforming growth factor- (TGF-) alsonal transduction [79]. By contrast, the direct pathway
stimulates interstitial fibrosis of the peritoneum [84].works before generation of AGEs and ALEs. The RCOs
A closer analysis of the interrelationship betweendirectly attack target molecules on cell surfaces or inside
RCOs, AGEs, VEGF, eNOS and NO discloses the com-the cells, which initiate the subsequent signal transduc-
plexity of the possible pathogenic pathways leading totion [80–83]. For example, GO and MGO possess two
angiogenesis in the peritoneum. Accumulation of RCOsreactive carbonyl groups to make protein aggregates by
and AGEs in the peritoneum activates endothelial cells,cross-linking, which may amplify the signals for tyrosine
which promotes VEGF expression. In turn, VEGF furtherphosphorylation of cellular proteins [80]. The binding
stimulates endothelial cells with an attendant up-regula-of 4-hydroxynonenal (HNE), a major RCO generated
tion of eNOS and the release of NO. The latter contrib-during membrane lipid peroxidation, with epidermal
utes, at least in part, to the angiogenic effect of growthgrowth factor receptor (EGFR) induces its clustering on
factors such as VEGF. Vascular proliferation and in-the cell surface, thereby activating the mitogen-activated
creased endothelial area lead to a further up-regulationprotein (MAP) family kinases [81].
of eNOS in the peritoneum, and, in some conditions, to
sustained release of NO. The latter has a threefold effect.
HYPOTHESIS First, it may act as a negative feedback and down-regu-
late the expression of VEGF [85]. Second, it might targetThese new data cast some light on putative mecha-
nisms of peritoneal membrane deterioration in long-term critical cysteine residues and regulate proteins by S-nitro-
sylation [43, 44]. Third, it might decrease AGE produc-PD patients. They include neoangiogenesis, enhanced
growth factor expression, elevated RCO content in the tion and quench its consequences [86]. Finally, in case
of oxidative stress, NO might combine with superoxideperitoneal cavity, advanced glycation and lipoxidation
of peritoneal membrane proteins, and up-regulation of and generate peroxynitrite, a labile, cytotoxic reactive
oxidant species [87].NOS expression with an increased bioactive NO release.
In this section, we provide a hypothetical framework to These hypothetical mechanisms open a number of
therapeutic approaches that might protect the peritonealintegrate them with the intent to provide clues for future
investigations and, possibly, for innovative therapeutic membrane against the consequences of long-term PD.
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Fig. 1. Hypothesized structural and functional
alterations of the peritoneal membrane in long-
term peritoneal dialysis (PD). In chronic uremia,
plasma reactive carbonyl compounds (RCOs)
derived from both carbohydrates and lipids
accumulate in the circulation and slowly dif-
fuse into the peritoneal cavity. Biochemical
alterations in the peritoneum inherent to ure-
mia are exacerbated by the PD procedure
itself. During PD, RCOs resulting from heat-
sterilization of glucose PD fluid enter the peri-
toneum and are complemented by an in-
creased mass transfer of serum RCOs (os-
motic effect). The “peritoneal carbonyl stress”
accelerates the advanced glycation end prod-
uct (AGE) and advanced lipoxidation end
product (ALE) modification of the peritoneal
membrane. AGEs as well as their RCO pre-
cursors initiate a number of cellular responses,
including cytokine and growth factors [vascu-
lar endothelial growth factor (VEGF), basic
fibroblast growth factor-2 (FGF2) and trans-
forming growth factor- (TGF-)] produc-
tion, vascular smooth muscle cell prolifera-
tion, and specific nitric oxide synthase (NOS)
up-regulation. Enhanced VEGF and FGF2
expression, together with an augmented nitric
oxide (NO) release, stimulate angiogenesis
and vasodilation and increase the permeabil-
ity of peritoneal capillaries. These combined
modifications increase the effective peritoneal
surface area (EPSA). The latter augments the
permeability for small solutes and glucose,
stimulates glucose reabsorption, and results in
faster than normal dissipation of the osmotic
gradient across the peritoneal membrane with
an eventual loss of ultrafiltration. The up-reg-
ulation of FGF2 and TGF- stimulates inter-
stitial fibrosis of the peritoneum.
INNOVATIVE APPROACHES TO and to improve nutrition by replacing glucose with ico-
MORE EFFECTIVE AND BIOMEDICALLY dextrin or amino acids [88–90]. An advantage of these
MORE SUITABLE PERITONEAL newer solutions accrues from their lower RCO content.
DIALYSIS TECHNOLOGIES GO, MGO, 3-DG as well as total RCO levels are mark-
edly reduced in fresh icodextrin and amino acid PD fluidCarbonyl stress, increased NO secondary to NOS up-
when compared with heat-sterilized glucose PD fluidregulation, and up-regulation of VEGF and FGF2 cause
[91]. As a consequence, pentosidine and CML genera-some of the morphologic and molecular alterations of the
tion during incubation is lower in icodextrin and aminoperitoneal membrane. Their manipulation might provide
acid PD fluid than in conventional glucose PD fluidsome therapeutic benefits (Fig. 2).
[91, 92].
Reduction of the RCO content in peritoneal dialysis The benefits of a lower RCO content of PD fluid are
fluid or in peritoneal cavity mitigated by the changes in peritoneal fluid RCO content
occurring during dwell time [91]. Individual RCOs, suchAs previously stated, peritoneal protein modifications
as GO, MGO and 3-DG, fall progressively in icodextrinare determined not only by RCOs originating from PD
effluents or remain undetectable in amino acid effluent.fluid, but also by RCOs originating from the uremic
By contrast, with dwell time, total RCOs accumulatedcirculation. Some strategies have been designed to re-
in uremic serum diffuse within the peritoneal cavity withduce the RCOs present in PD fluid, and may prove
an attendant increase of the AGE formation potentialrewarding despite the fact that they do not fully eliminate
of PD fluid. While the clinical benefits of these fluids forthe peritoneal carbonyl stress.
the preservation of the peritoneal membrane remain toGlucose-free PD fluids. Major efforts have been un-
dertaken over the last few years to sustain ultrafiltration be documented in long-term studies, these findings do
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Fig. 2. Innovative approaches to more effective and biomedically more suitable peritoneal dialysis technologies. Peritoneal membrane modifications
are determined by RCOs originating from both PD fluid and uremic circulation. PD fluid RCOs are lowered in non-glucose fluids or in multi-
compartment bag systems. Peritoneal cavity fluid RCOs metabolism is enhanced by thiol repletion and the addition of glyoxalase I and glutathione.
They are trapped by inhibitors of carbonyl amine chemistry or by RCO adsorbents. The increased release of NO, either by constitutive endothelial
nitric oxide synthase (eNOS) or by inducible nitric oxide synthase (iNOS) induced by peritoneal inflammation, increases the effective peritoneal
surface area (EPSA). These changes are reversible by NOS inhibitors, NO scavengers, and anti-angiogenic substances. The preservation of the
peritoneal membrane might require a combination of several therapeutic approaches.
not detract from the clinical merits of these glucose free results should be assessed with caution as a much longer
study period may be required to reveal any changes inPD fluids [88]. Icodextrin fluid sustains ultrafiltration pro-
file that is beneficial for long dwells by employing colloi- these parameters.
Inhibitor of carbonyl amine chemistry. An alternativedal, rather than crystalline, osmotic pressure, whereas
amino acid fluid improves nitrogen balance in patients therapeutic strategy might rely on compounds known to
inhibit AGE formation. Compounds, such as aminogua-with malnutrition and avoids the glucose overload, an
advantage in diabetic and obese patients. nidine, OPB-9195, and probably biguanides [99], contain
a hydrazine nitrogen atom that is able to react withMulti-compartment bag. An interesting approach to
lower the RCO content of glucose-containing PD fluid carbonyl groups and eventually form hydrazone [63].
Trapping of RCOs by these compounds thus should in-has been recently provided by a multi-compartment bag
system [93, 94]. In this system, glucose is kept at a low hibit the RCO modifications of proteins. Indeed, both
aminoguanidine and OPB-9195 inhibit in vitro the for-pH, separate from the electrolyte buffer (bicarbonate-
based) solution at a neutral pH. When both bags are mation of AGEs (CML and pentosidine) as well as that
of ALEs (MDA-lysine and HNE-protein adduct). AGEmixed, the final solution has a physiologic concentration
of bicarbonate, a reduced concentration of lactate, and generation (pentosidine) from incubated uremic plasma
also is inhibited, demonstrating that both compoundsa physiologic pH. Its RCO content and AGE generation
potential are very low despite conventional heat-steril- trap precursor RCOs of pentosidine accumulating in ure-
mic serum [60].ization and subsequent storage [95, 96].
The clinical effects of this new fluid have been recently We have demonstrated that addition of OPB-9195 or
aminoguanidine to commercial glucose PD fluids re-assessed up to two years [97, 98]. Both studies demon-
strated elevated effluent levels of cancer antigen (CA) duced the generation of pentosidine and CML [63], in
agreement with a previous study by Lamb et al [100], who125 and reduced levels of hyaluronic acid in their over-
night effluent, suggesting reduced proinflammatory po- reported that aminoguanidine inhibited the fluorescence
intensity on albumin incubated in heat-sterilized glucosetential and improved peritoneal membrane integrity.
After two years, membrane transport characteristics and PD fluid. We further documented a dramatic fall in GO,
MGO and 3-DG levels within 24 hours of incubation ofultrafiltration capacity were similar in the double bag and
in the control group [97]. Although encouraging, these PD fluids with OPB-9195 or aminoguanidine [63].
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These carbonyl-scavenging agents have further bene- interfere competitively with the binding of l-arginine
to NOS, are well-characterized NOS inhibitors [104].fits. They block carbonyl stress-mediated intracellular sig-
naling [80, 83]. Oral administration of OPB-9195 to rats, Despite their lack of specificity, NG-monomethyl-l-argi-
nine (L-NMMA) and its prodrug NG-nitro-l-arginineafter balloon injury of their carotid arteries, effectively
reduces neointima proliferation in arterial walls [62]. methyl ester (L-NAME) have proved to be the most
useful NOS inhibitors [104]. Newer compounds that areClinical trials of aminoguanidine as well as of OPB-
9195 in diabetic patients have been hampered, however, more selective toward iNOS [105] and alternative strate-
gies to modulate the biological activity of NO have beenby their neurotoxicity largely due to the trapping of pyri-
doxal [101]. Less toxic and more specific carbonyl stress considered, but remain to be characterized [106, 107].
Only a few studies have investigated the potential ofinhibitors need to be developed.
Glyoxalase detoxification. Reactive carbonyl com- NOS inhibitors on peritoneal membrane characteristics.
Addition of L-NMMA to PD fluid does not alter perito-pounds partly are detoxified by the glyoxalase pathway.
We recently observed a patient in whom a deficiency of neal permeability in a chronic PD model in rabbits [108];
however, in different rat models of peritonitis, the addi-glyoxalase I was associated with unusually elevated lev-
els of AGEs (pentosidine and CML) and their precursors tion of L-NAME to PD fluid increases net ultrafiltration
with a dose-dependent effect on the permeability for[102]. The causes of this deficiency remain unknown.
Nevertheless, the association of very low levels of glyoxa- small solutes and proteins [38, 109]. The usefulness of
NOS inhibition in long-term PD remains to be defined.lase I with strikingly elevated levels of AGEs and RCO
precursors offers new therapeutic insights in that maneu- Manipulation of an ubiquitous mediator such as NO
raises a number of potential problems and may actuallyvers augmenting glyoxalase I activity might lower RCO
and AGE levels. have a double-edged sword effect. Current efforts aim
towards improving the selectivity of NOS inhibitors, tak-Preliminary observations in vitro support this ap-
proach. Detoxification of RCOs by glyoxalase I is mark- ing into account differences in expression levels, cofactor
utilization and location [104, 105].edly impaired by a decreased thiol concentration (such as
glutathione) [103]. Thiol compound such as glutathione,
Inhibitor of angiogenesiscysteine or N-acetylcysteine added to mixtures of GO,
MGO, 3-DG decreases their levels. Added to heat-steri- Based on recent insights [110], a spectrum of strategies
for the modulation of angiogenesis has emerged, withlized glucose PD fluid, they lower AGE generation after
incubation. Glutathione is undoubtedly less toxic in vivo the most successful approach to date being the use of
agents that inhibit endothelial cell growth [111]. Interfer-than aminoguanidine but, unfortunately, less efficient at
least in vitro. Addition of glyoxalase I overcomes this ence with factors such as VEGF and FGF2 and their
receptors may provide another approach. A third ap-limit. Utilized jointly, both compounds dramatically ac-
celerate and intensify the in vitro lowering of GO and proach is to interfere with endothelial cell adhesion and
migration [111].MGO both in RCO mixtures and in glucose-based PD
fluid. A similar effect is observed when glyoxalase I is Although more than 30 anti-angiogenesis compounds
have been tested in human clinical anti-cancer trials,replaced by lysates of glyoxylase I transfected cells or
by tissue extracts of human glyoxalase I transgenic mice trials for noncancerous diseases are scarce and limited
in scope [111]. No studies have been undertaken in long-[103]. These results open the exciting prospect of low-
ering the peritoneal carbonyl stress in humans by raising term PD, probably because appropriate animal models
are lacking [112]. It must be stressed that trials usingglyoxalase I activity in peritoneal cells by genetic engi-
neering (described below) or by the concomitant admin- anti-angiogenic substances require specific approaches
to overcome investigator bias [113], and that little infor-istration of recombinant glyoxalase I with glutathione.
RCO adsorbent. Compounds with RCO binding prop- mation on safety and long-term side-effects of this type
of therapy is available.erties might be immobilized on beads or in a cartridge
in order to adsorb RCOs in conventional heat-sterilized
Gene therapyglucose PD. Polystyrene sulfonyl hydrazide beads or
diaminoguanidine agarose beads added to heat-steri- Some of functional and structural changes associated
with long-term PD might be targeted by gene therapylized glucose PD fluid decrease the levels of GO and
MGO as well as the generation of pentosidine and CML [114]. Ex vivo gene therapy involves harvesting perito-
neum samples to isolate mesothelial cells that will beafter incubation (Miyata T and Ueda Y, unpublished
observation). genetically modified before re-implantation into the peri-
toneal cavity [115]. The feasibility of this procedure has
Inhibitor of the L-arginine-NO pathway been demonstrated in animal models by the production
of anti-inflammatory and anti-oxidant proteins from ge-Modulation of the activity of NO may have consider-
able therapeutic value. The l-arginine analogs, which netically modified cells following experimental denuda-
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C.M. Hoff, T.R. Shockley, M. Nakayama, S. Sugiyama, and M. Nangakution of the membrane or chronic exposure to dialysis
for helpful discussions.
solutions [115]. While reimplantation of autologous cells
Reprint requests to Toshio Miyata, M.D., Ph.D., Molecular and Cel-in PD patients has been accomplished, conditions for
lular Nephrology, Institute of Medical Sciences and Department of Inter-reseeding the peritoneal membrane on an acute or
nal Medicine, Tokai University School of Medicine, Bohseidai, Isehara,
chronic basis still need to be defined. In vivo gene trans- Kanagawa 259-1143, Japan.
E-mail: t-miyata@is.icc.u-tokai.ac.jpfer is based on direct gene delivery and in situ genetic
modification. The adenovirus system appears to be the
most efficient for delivering genes to a significant per- APPENDIX
centage of mesothelial cells [115]. However, its use in
Abbreviations used in this paper are: AGEs, advanced glycationvivo may be limited by local changes resulting from in- end products; ALEs, advanced lipoxidation end products; AQP-1,
flammatory and immune responses. aquaporin-1; CML, Nε-carboxymethyllysine; 3-DG, 3-deoxyglucosone;
EPSA, effective peritoneal surface area; FGF2, basic fibroblast growthFuture prospects of gene therapy in the peritoneum
factor; GO, glyoxal; HNE, 4-hydroxynonenal; MDA, malondialde-include using either non-viral systems or viruses with hyde; MGO, methylglyoxal; NO, nitric oxide; NOS, nitric oxide syn-
low potential for immunogenicity, increasing gene transfer thase; PD, peritoneal dialysis; RCO, reactive carbonyl compound;
VEGF, vascular endothelial growth factor.efficiency, and regulating transgene expression through
use of mesothelial cell-specific promoters [116].
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